Abiopharma

🔍 Buell Jennifer (Executive)

Company: MiNK Therapeutics, Inc. (INKT)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 31,474 shares of Common Stock at $11.12 per share (Direct)
  Date: 2026-01-02 | Code: A | equity_swap_involved: false | shares_owned_after: 67,966.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 50,000 shares of Stock Option (Right to Buy) at $11.12 per share (Derivative)
  Date: 2026-01-02 | Code: A | Expires: 2036-01-02 | equity_swap_involved: false | shares_owned_after: 50,000.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Reflects the executive's 2025 performance bonus award paid in MiNK Therapeutics, Inc. common stock. The stock issued is fully-vested on the date of issuance but is subject to a lockup restriction with 100% of the award released on February 2, 2026.
• F2: $11.12 was the fair market value of MiNK Therapeutics, Inc. Common Stock on January 2, 2026, the stock issuance date.
• F3: The option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the date of grant, with the remainder vesting in eight equal quarterly installments thereafter.